STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] 2seventy bio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

The reporting persons — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin — submitted a Schedule 13G/A with respect to 2seventy bio, Inc.'s common stock. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest and reports zero shares and 0% ownership. The cover information lists reporting-person classifications including IA, OO, PN, HC, and IN.

The filing contains certifications that the securities were acquired and are held in the ordinary course of business and were not acquired to influence control. The submission states no sole or shared voting or dispositive power for any reporting person and attaches Exhibit 99.1 (agreement regarding joint filing).

Positive
  • Clear disclosure that each reporting person holds 0 shares (0%) of the issuer's common stock
  • Certifications stating securities were acquired and are held in the ordinary course of business
  • Attachment of Exhibit 99.1 documenting the agreement regarding joint filing, supporting transparency
Negative
  • None.

Insights

TL;DR: Beryl and affiliates report no economic or voting interest in 2seventy bio; this filing is informational and has no effect on the cap table.

The Schedule 13G/A discloses 0 shares (0%) beneficially owned by each named reporting person and confirms no sole or shared voting/dispositive powers. From a market-impact perspective, the filing conveys no change to ownership concentration or potential activism risk. The certifications that holdings are in the ordinary course further indicate this is a routine disclosure rather than a strategic acquisition or control attempt.

TL;DR: No reported ownership or control rights by the filers; governance and shareholder structure remain unchanged.

The document includes explicit disclaimers that the filers do not claim beneficial ownership beyond pecuniary interest and shows no voting or dispositive authority. The attached joint-filing agreement (Exhibit 99.1) documents coordination on the filing but does not reflect share accumulation. For governance analysis, there are no new shareholder nominees, control assertions, or changes to board voting dynamics arising from this filing.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Beryl Capital Management LLC
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer
Date:07/31/2025
Beryl Capital Management LP
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:07/31/2025
Beryl Capital Partners II LP
Signature:/s/ Andrew Nelson
Name/Title:COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:07/31/2025
David A. Witkin
Signature:/s/ David A. Witkin
Name/Title:Reporting person
Date:07/31/2025
Exhibit Information

Exhibit 99.1 - Agreement Regrding Joint Filing of Statement on Schedule 13D or 13G

FAQ

How many shares of 2seventy bio (TSVT) do the reporting persons own?

The filing reports 0 shares beneficially owned by each reporting person, representing 0% of the class.

Which entities and individuals filed the Schedule 13G/A for TSVT?

The filing was made by Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin.

Do the filers claim voting or dispositive power over TSVT shares?

No. The schedule reports no sole or shared voting power and no sole or shared dispositive power for any reporting person.

Does this Schedule 13G/A indicate an attempt to influence control of 2seventy bio?

No. The certifications state the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control.

Is there any agreement or exhibit attached to the filing?

Yes. The filing references Exhibit 99.1, an agreement regarding the joint filing of the statement.
2Seventy Bio

NASDAQ:TSVT

TSVT Rankings

TSVT Latest News

TSVT Latest SEC Filings

TSVT Stock Data

266.14M
49.56M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
Link
US
CAMBRIDGE